Strategy

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">Metamorphoses of Ovid</h1><h2 class="title-bottom webtitle">How Ovid will work with patients to repurpose drugs for rare brain disease</h2><div class="byline">Susan Schaeffer, Editor</div><div class="date"></div></div></div></div>

Endocrine / Metabolic

Neurology

Ophthalmic

Metamorphoses of Ovid

Newco Ovid is working with patients and families to develop failed drugs for rare and Orphan brain diseases, starting with Angelman syndrome.

How Ovid will work with patients to repurpose drugs for rare brain disease

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>

Paywall Not Entitled Title

Request a Trial

Purchase This Article

<center><span style="font-weight:300;">[Log in]{{login}}</span></center>

Paywall Sub log in

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

BioCentury-BayHelix East-West BioPharma Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home